Chloroform

Chloroform

SCHEMBL3074804

ClC(Cl)Cl.O=C(C=Cc1ccccc1)C=Cc1ccccc1

nearest known ligand 0.83

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.83
▸ CYP2C9 P11712 3/20 0.83
▸ MAPT P10636 3/20 0.83
▸ PLIN1 O60240 2/20 0.83
▸ LMNA P02545 2/20 0.83
▸ RECQL P46063 2/20 0.83
▸ PLIN5 Q00G26 2/20 0.83
▸ ABHD5 Q8WTS1 2/20 0.83
▸ CYP2D6 P10635 2/20 0.83
▸ F3 P13726 2/20 0.83
▸ ALDH1A1 P00352 2/20 0.83
▸ SMN1; SMN2 Q16637 1/20 0.83
▸ HDAC3 O15379 2/20 0.61
▸ HDAC4 P56524 2/20 0.61
▸ HDAC1 Q13547 2/20 0.61
▸ HDAC2 Q92769 2/20 0.61
▸ HDAC8 Q9BY41 2/20 0.61
▸ HDAC6 Q9UBN7 2/20 0.61
▸ TNKS O95271 1/20 0.61
▸ HCAR2 Q8TDS4 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Chloroform SCHEMBL1654667 1.00 CYP1A2 (0.83) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL5751924 1.00 CYP1A2 (0.83) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL1043119 1.00 CYP1A2 (0.83) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL84057 0.98 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL29371090 0.98 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL28370740 0.98 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL18788602 0.98 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL2128849 0.98 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL2832028 0.98 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA
Chloroform SCHEMBL7629150 0.98 CYP1A2 (0.79) CYP1A2CYP2C9MAPTPLIN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115054600-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2024-06-14 — — CN disclosed
CN-118103428-A Organic semiconductor material 东洋纺株式会社 2024-05-28 — — CN disclosed
CN-115054600-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-16 — — CN disclosed
CN-114984003-A Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-09-02 — — CN disclosed
CN-109415321-B Aromatic sulfonamide derivatives 拜耳制药股份公司 2022-06-17 — — CN disclosed
CN-111263762-A Novel compound and organic electroluminescent element 出光兴产株式会社 2020-06-09 — — CN disclosed
CN-109890818-A PESTICIDALLY ACTIVE HETEROCYCLIC DERIVATIVES WITH SULPHUR AND HYDROXYLAMINE SUBSTITUENTS 先正达参股股份有限公司 2019-06-14 — — CN disclosed
CN-102105507-B Polymer, light-emitting layer material, organic electroluminescent element material, composition for organic electroluminescent element, organic electroluminescent element using same, solar cell element, organic EL display device, and organic EL lighting MITSUBISHI CHEM CORP 2014-09-03 — — CN disclosed
CN-102690216-A Method for producing N-acylamino acid SUMITOMO CHEMICAL CO 2012-09-26 — — CN disclosed
CN-102171190-A Insecticidal benzenedicarboxamide derivative BAYER CROPSCIENCE AG 2011-08-31 — — CN disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 — — EP disclosed
CN-100400538-C 5HT for the treatment of diabetes and obesity2cReceptor agonists HOFFMANN LA ROCHE (CH) 2008-07-09 — — CN disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 — — US disclosed
CN-1290847-C Aza-aryl piperazines HOFFMANN LA ROCHE (CH) 2006-12-20 — — CN disclosed
EP-1419155-B1 PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS SMITHKLINE BEECHAM PLC (GB) 2006-11-08 — — EP disclosed
CN-1812989-A 5ht2c receptor agonists for the treatment of diabetes and obesity HOFFMANN LA ROCHE (CH) 2006-08-02 — — CN disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 — — EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 — — WO disclosed
CN-1625558-A Aza-arylpiperazines HOFFMANN LA ROCHE (CH) 2005-06-08 — — CN disclosed
US-20040198756-A1 Medicaments SMITHKLINE BEECHAM PLC (GB) 2004-10-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010511-A1 Organic compounds REN, ACE, ACE2 CYP1A2 51/4885CYP2C9 63/4885MAPT 2397/4885
US-20040198756-A1 Medicaments PIGO, PSAP, CD68 CYP1A2 2907/4885CYP2C9 4332/4885MAPT 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback